Organization Profile

You just read:

Pivotal Therapeutics VASCAZEN®-REVEAL trial meets primary and secondary endpoints - VASCAZEN® shows 121% correction of an Omega-3 deficiency (p< 0.0001) with a concomittant 48% reduction in triglycerides (p<0.0005)

News provided by

Pivotal Therapeutics Inc.

May 07, 2013, 10:55 ET